Clark A. Sehon
GlaxoSmithKline (United States)(US)
Publications by Year
Research Areas
Immune Response and Inflammation, Cell death mechanisms and regulation, Protein Kinase Regulation and GTPase Signaling, Protease and Inhibitor Mechanisms, Catalytic Alkyne Reactions
Most-Cited Works
- → Toll-like Receptor 3-mediated Necrosis via TRIF, RIP3, and MLKL(2013)918 cited
- → MLKL Compromises Plasma Membrane Integrity by Binding to Phosphatidylinositol Phosphates(2014)805 cited
- → RIP3 Induces Apoptosis Independent of Pronecrotic Kinase Activity(2014)599 cited
- → Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases(2017)466 cited
- → Total Syntheses of Ningalin A, Lamellarin O, Lukianol A, and Permethyl Storniamide A Utilizing Heterocyclic Azadiene Diels−Alder Reactions(1998)381 cited
- → Synthesis of Furans and 2,5-Dihydrofurans by Ag(I)-Catalyzed Isomerization of Allenones, Alkynyl Allylic Alcohols, and Allenylcarbinols(1995)192 cited
- → Development of Dihydropyridone Indazole Amides as Selective Rho-Kinase Inhibitors(2006)154 cited
- → Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases(2008)72 cited
- → Total Synthesis of the Enantiomer of the Furanocembrane Rubifolide(1997)69 cited
- → Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase(2019)68 cited